TP53 and PTEN inactivation is crucial for resistance to abiraterone and progression from adenocarcinoma to castrate-resistant prostate cancer (CRPC) with neuroendocrine differentiation (CRPC-NE) by transdifferentiation [103]. Here, TP53 is linked to adenocarcinoma.